Erenumab-aooe
Erenumab-aooe
Erenumab-aooe (pronunciation: eh-REN-oo-mab), also known as Aimovig, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that works by blocking the calcitonin gene-related peptide receptor (CGRP receptor), which plays a crucial role in migraine pathophysiology.
Etymology
The name "Erenumab" is derived from the drug's molecular structure. The suffix "-mab" is used for monoclonal antibodies, while "Erenumab" is specific to this particular drug. The term "aooe" is an arbitrary four-letter suffix assigned by the United States Adopted Names (USAN) council to distinguish the drug from others in its class.
Usage
Erenumab-aooe is administered once a month via subcutaneous injection. It is used when other migraine preventive medications have not worked or have caused problematic side effects. It is not used to treat a migraine that has already begun.
Side Effects
Common side effects of Erenumab-aooe include injection site reactions, constipation, and muscle spasms. Serious side effects may include allergic reactions.
Related Terms
External links
- Medical encyclopedia article on Erenumab-aooe
- Wikipedia's article - Erenumab-aooe
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski